ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 0181 • ACR Convergence 2024

    Integrated Multidisciplinary Lupus Social Work Program to Manage Social Determinants of Health in SLE and Lupus Nephritis – Preliminary Results

    Kimberly DeQuattro1, Stephanie DeVaughn2, Andrew Kanoff3 and Abdallah Geara1, 1University of Pennsylvania, Philadelphia, PA, 2Uniersity of Pennsylvania, Pennsylvania, 3University of Pennsylvania, Philadelphia, PA, Philadelphia, PA

    Background/Purpose: Minoritized individuals with systemic lupus erythematosus (SLE) experience social determinants of health (SDOH) challenges that affect access to care and increase the risk for…
  • Abstract Number: 0212 • ACR Convergence 2024

    Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample

    Brandon Blau1, Kelsey Gripp1, Catherine MacLean2 and Bella Mehta2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…
  • Abstract Number: 0428 • ACR Convergence 2024

    Placental Characteristics in Systemic Lupus Erythematosus Pregnancies Resulting in Small for Gestational Age Infants

    Rashmi Dhital1, Marni Jacobs2, Chelsey Smith3 and Mana Parast2, 1UC San Diego, Brentwood, TN, 2UC San Diego, San Diego, CA, 3UC San Diego, LA JOLLA, CA

    Background/Purpose: About a quarter of pregnant individuals with systemic lupus erythematosus (SLE) have small for gestational age (SGA) infants. We aim to characterize placental pathology…
  • Abstract Number: 0610 • ACR Convergence 2024

    Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)

    Xiaoping hong and liancheng lin, The Second Clinical Medical College of Jinan University, Shenzhen, China (People's Republic)

    Background/Purpose: To evaluate the clinical effectiveness of IFI44L gene methylation detection for the diagnosis of Systemic Lupus Erythematosus (SLE) by MS-HRM, to determine  the relative…
  • Abstract Number: 0628 • ACR Convergence 2024

    Genetic Determinants of Childhood Onset Systemic Lupus Erythematosus

    Meghan Nelson1, Shanta Murthy2, Sushma Maddipatla2, Sreekala Shenoy2, Lori Ponder3, Subra Kugathasan4, Dave Cutler5 and Sampath Prahalad6, 1Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America; Children’s Healthcare of Atlanta, Atlanta, United States of America; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland; Department of Human Genetics; Emory University School of Medicine, Atlanta, Georgia, United States of America, Bethesda, MD, 2Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America, Atlanta, GA, 3Children's Healthcare of Atlanta, Atlanta, GA, 4Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America; Children’s Healthcare of Atlanta, Atlanta, United States of America, Atlanta, GA, 5Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America, Atlanta, GA, 6Emory + Children's Pediatric Institute, Atlanta, GA

    Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a multisystem autoimmune disease with significant morbidity and mortality. Genome-wide association studies have identified more than 100 variants…
  • Abstract Number: 0647 • ACR Convergence 2024

    Clinical Associations and Outcomes of Pericarditis in Systemic Lupus Erythematosus

    Pankti Mehta1, Fadi Kharouf2, Qixuan Li3, Laura Patricia Whittall Garcia3, Dafna Gladman4 and Zahi Touma1, 1University of Toronto, Toronto, ON, Canada, 2University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Pericarditis is an important feature in the classification criteria and disease activity assessments in Systemic Lupus Erythematosus (SLE). We aimed to study the prevalence,…
  • Abstract Number: 0665 • ACR Convergence 2024

    Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis

    Nicolai Leuchten1, Ioannis Parodis2, Ralph Brinks3 and Martin Aringer1, 1University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 2Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 3University Witten/Herdecke, Witten, Germany

    Background/Purpose: Belimumab has well-established efficacy in improving overall SLE disease activity and in preventing flares and organ damage. In clinical routine, however, the primary goal…
  • Abstract Number: 0815 • ACR Convergence 2024

    Interferon-stimulated Gene Expression in Non-lesional Skin Is Similarly Elevated in Incomplete SLE and SLE

    Svenja Henning1, Lam Tsoi2, Benjamin Klein2, Celine Berthier2, Joseph Kirma2, Rachael Wasikowski3, Gilles Diercks4, Barbara Horvath1, Hendrika Bootsma5, Johann Gudjonsson2, Johanna Westra4, Karina de Leeuw6 and J. Michelle Kahlenberg2, 1University of Groningen, Groningen, Netherlands, 2University of Michigan, Ann Arbor, MI, 3Michigan, Dept. of Dermatology, Ann Arbor, MI, 4University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, 5Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 6University Medical Center Groningen, Groningen, Groningen, Netherlands

    Background/Purpose: Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria are referred to as incomplete SLE (ILE). These patients are…
  • Abstract Number: 0986 • ACR Convergence 2024

    State-and-County-Level Social Vulnerability Index and Trends in Systemic Lupus Erythematosus-Related Mortality in the U.S

    Omer Pamuk1, Ansaam Daoud2, Hasan Cetin3 and Marina Magrey4, 1University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, 2Case Western Reserve University/University Hospitals, Akron, OH, 3Cleveland Clinic Cole Eye Institute, Cleveland, OH, 4Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH

    Background/Purpose: Epidemiological studies have shown significant health disparities in systemic lupus erythematosus (SLE). The Centers for Disease Control and Prevention (CDC) developed the social vulnerability…
  • Abstract Number: 1227 • ACR Convergence 2024

    Longitudinal Patterns of Fibromyalgia Phenotypes in Patients with Systemic Lupus Erythematosus

    Brooke Cohen1, Philip Carlucci2, Kelly Corbitt3, Mala Masson4, Amit Saxena5, H Michael Belmont5, Chung-E Tseng6, Rachel Wu7, Hamleini Martinez7, George Kenefati7, Lisa Doan7, Jing Wang8, Kamil Barbour9, Heather Gold7, Jill Buyon10 and Peter Izmirly11, 1NYU Langone, NYC, NY, 2New York University School of Medicine, New York, NY, 3University of Miami Miller School of Medicine, El Portal, FL, 4NYU Langone Medical Center- Division of Rheumatology, New York, NY, 5NYU School of Medicine, New York, NY, 6NYU Langone Health, Flushing, NY, 7NYU Langone Health, NYC, 8NYU Langone Health, NYC, NY, 9CDC, Alpharetta, GA, 10NYU Grossman School of Medicine, New York, NY, 11New York University Grossman School of Medicine, New York, NY

    Background/Purpose: Fibromyalgia (FM) is a common comorbidity in patients with systemic lupus erythematosus (SLE) and a major contributor to poor health related quality of life.…
  • Abstract Number: 1277 • ACR Convergence 2024

    Why Did You Choose That Score? – Associations Between Patient Global Assessment Scores and Mental Health in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus

    Inna Powers1, Sonja Ziniel2, Jeanelle Sheeder3, Jessica Bloom4 and Brian Pitts1, 1University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, 2University of Colorado School of Medicine, Aurora, CO, 3University of Colorado School of Medicine, Department of Obstetrics and Gynecology, Aurora, CO, 4University of Colorado, Denver, CO

    Background/Purpose: Rheumatic disease in childhood significantly alters a child’s quality of life. The patient global assessment (PGA) score is a clinical and research tool that…
  • Abstract Number: 1492 • ACR Convergence 2024

    Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE

    Edward Vital1, Richard Furie2, Eric Morand3, Ian Bruce4, Jacob Knagenhjelm5 and Catharina Lindholm6, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, 2Northwell Health, Manhasset, NY, 3School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 4Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 5BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, 6BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden

    Background/Purpose: SLE is a chronic disease in which irreversible organ damage can accumulate over time; treatments associated with rapid responses in patients are therefore desirable.1…
  • Abstract Number: 1508 • ACR Convergence 2024

    Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients

    Yuko Shirota1, Misa Oguma2, Ryo Kuwata3, Yumi Tajima4, Yumiko Oka5, Miki Takeshita2, Takao Kodera2 and Tomonori Ishii2, 1Tohoku University Hospital / Department of Hematology and Rheumatology, Sendai, Japan, 2Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Japan, 3National Center for Global Health and Medicine / Division of Rheumatic Diseases, Shinjyuku, Tokyo, Japan, 4Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Miyazaki, Japan, 5Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai

    Background/Purpose: In recent years, the number of older patients with systemic lupus erythematosus (SLE) in Japan has been increasing, with particular attention to those developing…
  • Abstract Number: 1525 • ACR Convergence 2024

    Early versus Late Lupus Nephritis: A Meta-analysis of Observational Studies

    Alexandre Matar1 and Omer Pamuk2, 1MetroHealth, Westlake, OH, 2University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder characterized by a broad range of clinical and immunological manifestations, one of which is…
  • Abstract Number: 1544 • ACR Convergence 2024

    Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus

    wanling wei, ling lei, Cheng Zhao, hanyou mo, zhanrui chen, leting zheng, jing wen, Fang Qin, xiaoling liao, wen zeng and fei dong, The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic)

    Background/Purpose: B cells play an important role in the pathogenesis of systemic lupus erythematosus(SLE).Multiple biological agents with B lymphocyte as the therapeutic target have recently emerged…
  • « Previous Page
  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology